Granules India Q1 FY27 Results: Standalone Profit Declines to ₹717.46 Cr, Consolidated Profit at ₹1,799.63 Cr
Granules India reported Q1 FY27 results with standalone profit at ₹717.46 crore, down from ₹989.87 crore year-on-year. Consolidated profit surged to ₹1,799.63 crore from ₹701.56 crore. Standalone revenue was ₹8,018.77 crore, and consolidated revenue was ₹14,767.74 crore.
The results show a mixed performance with a decline in standalone profit but a substantial increase in consolidated profit. This mixed outcome warrants a medium impact assessment as it provides both concerns and positive indicators for investors.
The standalone profit has decreased year-on-year, which is a negative factor. However, the consolidated profit has seen a significant increase, which is positive. The overall sentiment is neutral due to these mixed results.
Granules India Limited announced its unaudited financial results for the first quarter ended June 30, 2026. The company's Board of Directors approved these results during a meeting held on July 21, 2026, which commenced at 10:15 AM and concluded at 12:00 PM.
On a standalone basis, the company reported a profit after tax of ₹717.46 crore for the quarter. This compares to a profit of ₹989.87 crore in the same quarter of the previous year. Revenue from operations for the standalone entity stood at ₹8,018.77 crore.
The consolidated financial results for the group show a profit after tax of ₹1,799.63 crore for the first quarter ended June 30, 2026. This is an increase from the ₹701.56 crore profit reported in the corresponding quarter of the previous year. Consolidated revenue from operations was ₹14,767.74 crore.
The company also provided details on other comprehensive income and earnings per share for both standalone and consolidated results. The auditor's limited review report confirms that the financial statements are prepared in accordance with Indian Accounting Standards (Ind AS) and comply with SEBI regulations. The company operates in a single reportable business segment: Pharmaceutical products, including ingredients and intermediaries.
What to do with a filing like this
Granules India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Granules India Limited. Read the original for the full detail.